Published in Drug Alcohol Depend on January 12, 2010
Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther (2012) 1.20
Critical illness induces nutrient-independent adipogenesis and accumulation of alternatively activated tissue macrophages. Crit Care (2013) 0.94
Thermal latency studies in opiate-treated mice. J Pharm Bioallied Sci (2014) 0.77
Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend (2012) 0.75
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature (1995) 6.72
Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science (1995) 5.74
An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther (2006) 2.82
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther (2001) 2.00
Hormesis and medicine. Br J Clin Pharmacol (2008) 1.91
Interactions between drugs and occupied receptors. Pharmacol Ther (2006) 1.53
Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol (2004) 1.51
Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol (2004) 1.48
Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain (1998) 1.11
Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm (2007) 1.04
Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol (1997) 1.02
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol (2009) 0.92
Buprenorphine: high-affinity binding to dorsal spinal cord. J Neurochem (1982) 0.86
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther (2004) 1.89
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86
A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A (2005) 1.82
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol (2004) 1.51
2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther (2007) 1.22
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther (2010) 1.07
Expression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammation. Atherosclerosis (2008) 1.05
Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol (2004) 1.05
Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) (2008) 1.04
Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav (2009) 1.03
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin (2013) 1.02
Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther (2003) 1.01
Higher expression of Bax in regulatory T cells increases vascular inflammation. Front Biosci (2008) 0.98
An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav (2007) 0.97
A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract (2012) 0.97
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. Eur J Pharmacol (2008) 0.97
Nicotine behavioral pharmacology: clues from planarians. Drug Alcohol Depend (2011) 0.95
Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. J Pharmacol Toxicol Methods (2010) 0.95
Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice. Peptides (2010) 0.94
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behav Pharmacol (2010) 0.94
Transversus abdominis block: clinical uses, side effects, and future perspectives. Pain Pract (2013) 0.94
Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav (2006) 0.93
Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol (2002) 0.93
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol (2009) 0.92
A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res (2006) 0.91
Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. Pain Pract (2011) 0.91
Icilin induces a hyperthermia in rats that is dependent on nitric oxide production and NMDA receptor activation. Eur J Pharmacol (2007) 0.91
Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neurosci Lett (2009) 0.90
Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit. Eur J Pharmacol (2006) 0.90
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology (Berl) (2011) 0.88
Sucrose produces withdrawal and dopamine-sensitive reinforcing effects in planarians. Physiol Behav (2013) 0.88
Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth (2012) 0.86
Mu and kappa opioid receptor agonists antagonize icilin-induced wet-dog shaking in rats. Eur J Pharmacol (2006) 0.86
Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5'-guanidinonaltrindole-induced scratching models in mice: behavioral and neuroanatomical evidence. Eur J Pharmacol (2009) 0.85
Measurement of glutamate and aspartate in Planaria. J Pharmacol Toxicol Methods (2005) 0.85
Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig. J Pharmacol Exp Ther (2011) 0.85
Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J (2012) 0.85
Analgesic efficacy of buprenorphine in the presence of high levels of SDF-1α/CXCL12 in the brain. Drug Alcohol Depend (2010) 0.83
Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav (2006) 0.83
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) (2011) 0.82
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol (2008) 0.82
Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. J Pain Res (2012) 0.82
A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. J Pharmacol Toxicol Methods (2004) 0.82
Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose. Brain Res (2004) 0.81
Withdrawal-like behavior in planarians is dependent on drug exposure duration. Neurosci Lett (2008) 0.81
Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur J Pharm Sci (2002) 0.81
Icilin-induced wet-dog shakes in rats are dependent on NMDA receptor activation and nitric oxide production. Pharmacol Biochem Behav (2009) 0.80
Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians. Synapse (2008) 0.80
Differential behavioral effect of the TRPM8/TRPA1 channel agonist icilin (AG-3-5). Eur J Pharmacol (2007) 0.80
Planarians in pharmacology: parthenolide is a specific behavioral antagonist of cocaine in the planarian Girardia tigrina. Int J Dev Biol (2012) 0.80
Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother (2011) 0.79
Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians. Neuropeptides (2008) 0.79
Differential antinociceptive effects of buprenorphine and methadone in the presence of HIV-gp120. Drug Alcohol Depend (2011) 0.79
Behavioral characterization of serotonergic activation in the flatworm Planaria. Behav Pharmacol (2008) 0.79
Tapentadol extended release for chronic pain patients. Adv Ther (2013) 0.79
Opioid antagonists for pain. Expert Opin Investig Drugs (2013) 0.79
Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin-induced diabetes in rats. Pharmacology (2005) 0.78
The Analgesic Interaction of Misoprostol with Nonsteroidal Anti-Inflammatory Drugs. Am J Ther (1996) 0.78
NMDA receptors modulate morphine-induced hyperthermia. Brain Res (2003) 0.78
In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett (2012) 0.78
Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. Pain Pract (2010) 0.78
Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf (2014) 0.78
Antipruritic and antihyperalgesic actions of loperamide and analogs. Life Sci (2002) 0.78
Scratching activates microglia in the mouse spinal cord. J Neurosci Res (2014) 0.78
Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum. Neuropharmacology (2006) 0.78
Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids. J Clin Pharm Ther (2002) 0.77
Brain delta2 opioid receptors mediate SNC-80-evoked hypothermia in rats. Brain Res (2005) 0.77
Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. J Pain Res (2012) 0.77
Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract (2008) 0.77
Isothermal titration calorimetric study of RNase-A kinetics (cCMP --> 3'-CMP) involving end-product inhibition. Pharm Res (2004) 0.77
Pain and obesity in the older adult. Curr Pharm Des (2014) 0.76
Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. J Pharmacol Toxicol Methods (2005) 0.76
Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol (2005) 0.76
Single millimeter wave treatment does not impair gastrointestinal transit in mice. Life Sci (2002) 0.76
Acetaminophen and metabolite: lack of effect on nitric oxide synthase (constitutive or inducible). Headache (2002) 0.76
Modulation of delta opioid-evoked hypothermia in rats by WAY 100635 and fluoxetine. Neurosci Lett (2006) 0.76
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations. Curr Pharm Des (2012) 0.76
Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med (2014) 0.76
Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids (2011) 0.76
An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. J Opioid Manag (2012) 0.75
Nitric oxide synthase mediates delta opioid receptor-induced hypothermia in rats. Eur J Pharmacol (2006) 0.75
Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend (2012) 0.75
Anal itch. Aust Fam Physician (2004) 0.75
'Null method' determination of drug biophase concentration. Pharm Res (2011) 0.75
Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation. Brain Res (2011) 0.75
Evaluation of a novel topical essential oxygen oil for the treatment of pain in acute tendinopathy and sprains. Muscles Ligaments Tendons J (2011) 0.75
LiCl attenuates M(1)AChR-mediated intrathecal pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacology (2002) 0.75
Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors. Brain Res (2005) 0.75
Peripheral kappa-opioid agonist, ICI 204448, evokes hypothermia in cold-exposed rats. Pharmacology (2005) 0.75
The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain. Adv Ther (2015) 0.75
Endothelin antagonists in CION injury model. Pain (2006) 0.75
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. Neurosci Lett (2010) 0.75
Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract (2014) 0.75
Capsaicin and nitric oxide synthase inhibitor interact to evoke a hypothermic synergy. Neurosci Lett (2006) 0.75